A best evidence topic in thoracic surgery was written according to a structured protocol. We looked at the clinical relevance of lymph node involvement and nodal (N) stage, in thymomas, thymic carcinomas and carcinoids. The possible role of lymphadenectomy in addition to thymectomy was also evaluated. A total of 605 papers were found, of which nine represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers were tabulated. In the Yamakawa-Masaoka classification, based on 226 patients, lymph nodes were classified as anterior mediastinal (N1), defined as nodes surrounding the thymus gland; intrathoracic (N2), all nodes within the thorax excluding N1; and extrathoracic nodes (N3). Kondo validated the Yamakawa-Masaoka classification in a multicentric cohort of 1320 patients. Thymomas presented nodal involvement in 1.8% of cases, carcinomas in 27% of cases, and carcinoids in 28% of cases. The role of nodal status in defining the stage was even more emphasized in the staging system developed by Tsuchiya for thymic carcinomas. In the Istituto Nazionale Tumori classification, thymomas with N1 or N2 were considered as locally advanced disease with a 95-month disease-free survival rate for locally advanced disease of 46.9 vs 98.6% for locally restricted disease (absence of nodal involvement). Weissferdt and Moran, on a series of 65 thymic carcinomas, underlined the clinical relevance of nodal involvement. Positive lymph nodes were associated with significantly worse survival (P = 0.01070). Okuma, in a series of 68 advanced stage thymic carcinomas, showed that curative-intent surgical treatment was related to prolonged survival (P = 0.03). In particular, IVb tumours due to node-only involvement had better survival when radical resection was achieved when compared with IVb due to distant metastases (P = 0.03). Sung et al. showed the importance of harvesting 10 or more lymph nodes and dissecting intrathoracic lymph nodes to ensure a more complete stadiation of thymic carcinomas. The results underline the clinical relevance and prognostic value of nodal involvement in thymic carcinomas and carcinoids. In these cases, lymphadenectomy is desirable to allow the real definition of N status.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is described int the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 63-year old man underwent extended thymectomy for a 4-cm thymic mass. Pathological evaluation demonstrated a B3 thymoma with a metastatic perithymic lymph node. Afterwards, you wonder about the prognostic value of nodal involvement in thymic epithelial tumors (TET), and whether or not a lymphadenectomy should be performed in addition to extended thymectomy.
SEARCH STRATEGY
Combined results of two searches using Medline 1990-2013 was performed using the PubMed interface 
SEARCH OUTCOME
Five hundred and eighty-three and 22 papers were found, respectively, and 9 papers provided the best evidence to answer the question (Table 1) . Although the limited number of patients prevents from drawing general guidelines on the topic, the study provides some indications for further speculation: definition of lymph node stations to be harvested and minimum number of lymph nodes required to achieve oncological adequacy 
RESULTS
The incidence and prognostic value of lymph nodal involvement in case of thymic malignancies have been reported in a few studies. However, at the present time, there are no guidelines about the role and extent of lymphadenectomy in the course of thymectomy for thymic neoplasms. Yamakawa et al. [2] defined nodal involvement as follows: anterior mediastinal (N1: nodes surrounding the thymus gland, generally removed during standard extended thymectomy); intrathoracic (N2: bilateral paratracheal, subaortic, hilar, intrapleural lymph nodes, all nodes excluding anterior mediastinal), and extrathoracic (N3). Kondo and Monden [3] validated the Yamakawa-Masaoka TNM in a cohort of 1320 patients. Thymomas presented nodal (N+) involvement in 1.8% of cases (73% N1, 27% N2, no N3), carcinomas in 27% (49/183) of cases (39% N1, 20.4% N1 + N2, 6% N1 + N3; 4% N1 + N2 + N3; 10.2% N2; 20.4% N3), and carcinoids in 28% (11/40) of cases (27.5% N1 only, 50% N2, 22.5% N3). For thymomas, the authors observed a significant difference in 5-year survival between N− and N+ patients (P <0.0001), although no difference between N1 and N2 was found. A significant difference in 5-year survival according to N status was observed in carcinomas and carcinoids (N0 56%; N1 42.1%, N2 29.3%, N3 18.8%).
Tsuchiya et al. [4] developed a classification with similar N descriptors, but different grouping. Stage I included encapsulated T1 or minimally invasive T2 (without diffusion to neighbouring organs) N0, Stage II T1-2 N1, all N2-N3 were considered IVb, while M+ were grouped in the novel IVc group. This classification allowed a better separation of survival curves between Stage I and III or IV, and between III and IV, indicating the importance of nodal involvement in prognosis. Istituto Nazionale Tumori (INT) classification identifies three stages: RD (radically treatable by surgery), LAD (requiring multimodality therapy) and SD (generally treated with chemo-radiotherapy). The N3 descriptor was limited to supraclavicular and prescalenic nodes only (other extrathoracic nodal metastases were considered M1b). N1 or N2 disease was considered LAD independent from the T descriptor, showing a worse prognosis when compared with LRD (T1N0: no invasion of capsule, T2N0: microscopic invasion/minimal diffusion to mediastinal fat; without nodal involvement).
Positive nodal status was associated with significantly worse survival (P = 0.01070) in the reports of Weissferdt and Moran [6, 7] . They proposed a three-stage system based on the data of 33 patients. Presence of any kind of intrathoracic lymph nodal metastases was defined as N1 and was considered as Stage III (the differentiation between N1 and N2 was not followed). Statistically significant differences in survival emerged between the proposed stages (P = 0.04178) but not between Masaoka or Tsuchiya stages (P = 0.07762, P = 0.09081).
Therefore, nodal involvement seems to have clinical relevance mainly in thymic carcinomas and carcinoids. Okuma et al. [8] , in a retrospective study about curative-intent treatment for thymic carcinoma in a cohort of 68 patients, showed that radical surgery was the only favourable prognostic factor (P = 0.03). In the IVb group, lymph node involvement without other distant metastases was a favourable prognostic factor. The author concludes that lymphatic metastases may be responsive to curative-intent surgery. Park et al. [9] evaluated the role of lymphadenectomy in a group of 37 thymic carcinomas. They divided the patients into four 
CLINICAL BOTTOM LINE
These results underlined the clinical relevance and prognostic value of nodal involvement in thymic carcinomas and carcinoids. In these subsets of TET, a TNM-based staging system should be employed to define prognosis better. As a consequence, the surgical approach should include a form of lymphadenectomy (encompassing both anterior mediastinal and intrathoracic nodes, such as right paratracheal) to allow nodal staging. The International Thymic Malignancy Interest Group (ITMIG) suggested the need of systematic sampling of intrathoracic lymph nodes in case of Stage III thymomas and in all cases for thymic carcinoma [10] . ITMIG is also developing a consensus-based node map for thymic malignancy in which two main mediastinal regions are identified (anterior and deep region) [11] . This map will certainly provide a fundamental basis for further clinical investigations.
